2020
Association Between Breastfeeding and Ovarian Cancer Risk
Babic A, Sasamoto N, Rosner BA, Tworoger SS, Jordan SJ, Risch HA, Harris HR, Rossing MA, Doherty JA, Fortner RT, Chang-Claude J, Goodman MT, Thompson PJ, Moysich KB, Ness RB, Kjaer SK, Jensen A, Schildkraut JM, Titus LJ, Cramer DW, Bandera EV, Qin B, Sieh W, McGuire V, Sutphen R, Pearce CL, Wu AH, Pike M, Webb PM, Modugno F, Terry KL. Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncology 2020, 6: e200421. PMID: 32239218, PMCID: PMC7118668, DOI: 10.1001/jamaoncol.2020.0421.Peer-Reviewed Original ResearchConceptsOvarian cancer riskInvasive ovarian cancerEpithelial ovarian cancerOvarian cancerCancer riskLower riskOdds ratioLogistic regressionHigh-grade serous subtypeHistotype-specific associationsMultivariable logistic regressionCase-control studyOvarian Cancer Association ConsortiumPolytomous logistic regressionParous womenEndometrioid cancerModifiable factorsPooled analysisSerous subtypeMAIN OUTCOMEBreastfeedingMore monthsOverall associationLethal typeCancer
2019
Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study
Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ, Group A, Risch H, Rossing M, Doherty J, Goodman M, Modugno F, Ness R, Moysich K, Kjær S, Høgdall E, Jensen A, Schildkraut J, Berchuck A, Cramer D, Bandera E, Rodriguez L, Wentzensen N, Kotsopoulos J, Narod S, McLaughlin J, Anton-Culver H, Ziogas A, Pearce C, Wu A, Lindström S, Terry K. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. International Journal Of Epidemiology 2019, 48: 822-830. PMID: 31211375, PMCID: PMC6659359, DOI: 10.1093/ije/dyz113.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeOvarian cancer riskOvarian Cancer Association ConsortiumSelf-reported polycystic ovary syndromeInvasive ovarian cancerOvarian cancerCancer riskOvary syndromeInverse associationOral contraceptive useReproductive-aged womenBody mass indexSingle nucleotide polymorphismsStrong inverse associationComplex endocrine disorderObservational study resultsMendelian randomization studyEuropean ancestry womenEndometrioid tumorsMass indexDecreased riskEndocrine disordersSpecific histotypesContraceptive useAged women
2018
Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium
Harris HR, Babic A, Webb PM, Nagle CM, Jordan SJ, Group O, Risch H, Rossing M, Doherty J, Goodman M, Modugno F, Ness R, Moysich K, Kjær S, Høgdall E, Jensen A, Schildkraut J, Berchuck A, Cramer D, Bandera E, Wentzensen N, Kotsopoulos J, Narod S, Phelan C, McLaughlin J, Anton-Culver H, Ziogas A, Pearce C, Wu A, Terry K, Consortium O. Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2018, 27: 174-182. PMID: 29141849, PMCID: PMC5877463, DOI: 10.1158/1055-9965.epi-17-0655.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerPolycystic ovary syndromeOvarian cancer riskMenstrual cycle lengthOvarian cancerCancer riskDecreased riskSelf-reported polycystic ovary syndromeLogistic regressionCycle lengthStudy-specific ORsIrregular menstrual cyclesSerous borderline tumorsRisk factor associationsCase-control studyOvarian cancer histotypesPolytomous logistic regressionMucinous tumorsOvary syndromeBorderline tumorsHistologic subtypeOvarian diseaseMenstrual cycleCancer histotypesHistotype
2015
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, EMBRACE, McGuffog L, Ellis S, Feng B, Buys S, Hopper J, Southey M, Tesoriero A, Investigators K, James P, Bruinsma F, Campbell I, Group A, Broeks A, Schmidt M, Hogervorst F, HEBON, Beckman M, Fasching P, Fletcher O, Johnson N, Sawyer E, Riboli E, Banerjee S, Menon U, Tomlinson I, Burwinkel B, Hamann U, Marme F, Rudolph A, Janavicius R, Tihomirova L, Tung N, Garber J, Cramer D, Terry K, Poole E, Tworoger S, Dorfling C, van Rensburg E, Godwin A, Guénel P, Truong T, Collaborators G, Stoppa-Lyonnet D, Damiola F, Mazoyer S, Sinilnikova O, Isaacs C, Maugard C, Bojesen S, Flyger H, Gerdes A, Hansen T, Jensen A, Kjaer S, Hogdall C, Hogdall E, Pedersen I, Thomassen M, Benitez J, González-Neira A, Osorio A, de la Hoya M, Segura P, Diez O, Lazaro C, Brunet J, Anton-Culver H, Eunjung L, John E, Neuhausen S, Ding Y, Castillo D, Weitzel J, Ganz P, Nussbaum R, Chan S, Karlan B, Lester J, Wu A, Gayther S, Ramus S, Sieh W, Whittermore A, Monteiro A, Phelan C, Terry M, Piedmonte M, Offit K, Robson M, Levine D, Moysich K, Cannioto R, Olson S, Daly M, Nathanson K, Domchek S, Lu K, Liang D, Hildebrant M, Ness R, Modugno F, Pearce L, Goodman M, Thompson P, Brenner H, Butterbach K, Meindl A, Hahnen E, Wappenschmidt B, Brauch H, Brüning T, Blomqvist C, Khan S, Nevanlinna H, Pelttari L, Aittomäki K, Butzow R, Bogdanova N, Dörk T, Lindblom A, Margolin S, Rantala J, Kosma V, Mannermaa A, Lambrechts D, Neven P, Claes K, Van Maerken T, Chang-Claude J, Flesch-Janys D, Heitz F, Varon-Mateeva R, Peterlongo P, Radice P, Viel A, Barile M, Peissel B, Manoukian S, Montagna M, Oliani C, Peixoto A, Teixeira M, Collavoli A, Hallberg E, Olson J, Goode E, Hart S, Shimelis H, Cunningham J, Giles G, Milne R, Healey S, Tucker K, Haiman C, Henderson B, Goldberg M, Tischkowitz M, Simard J, Soucy P, Eccles D, Le N, Borresen-Dale A, Kristensen V, Salvesen H, Bjorge L, Bandera E, Risch H, Zheng W, Beeghly-Fadiel A, Cai H, Pylkäs K, Tollenaar R, van der Ouweland A, Andrulis I, Knight J, OCGN, Narod S, Devilee P, Winqvist R, Figueroa J, Greene M, L. P, Loud J, García-Closas M, Schoemaker M, Czene K, Darabi H, McNeish I, Siddiquil N, Glasspool R, Kwong A, Park S, Teo S, Yoon S, Matsuo K, Hosono S, Woo Y, Gao Y, Foretova L, Singer C, Rappaport-Feurhauser C, Friedman E, Laitman Y, Rennert G, Imyanitov E, Hulick P, Olopade O, Senter L, Olah E, Doherty J, Schildkraut J, Koppert L, Kiemeney L, Massuger L, Cook L, Pejovic T, Li J, Borg A, Öfverholm A, Rossing M, Wentzensen N, Henriksson K, Cox A, Cross S, Pasini B, Shah M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Gronwald J, Agnarsson B, Kupryjanczyk J, Moes-Sosnowska J, Fostira F, Konstantopoulou I, Slager S, Jones M, in the genome P, Antoniou A, Berchuck A, Swerdlow A, Chenevix-Trench G, Dunning A, Pharoah P, Hall P, Easton D, Couch F, Spurdle A, Goldgar D. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal Of The National Cancer Institute 2015, 108: djv315. PMID: 26586665, PMCID: PMC4907358, DOI: 10.1093/jnci/djv315.Peer-Reviewed Original ResearchConceptsOvarian cancerBreast cancerVariant carriersCancer riskEstrogen receptor-negative breast cancerReceptor-negative breast cancerCancer case patientsInvasive ovarian cancerHormone-related cancersProstate cancer riskConfidence intervalsOvarian cancer riskSignificant inverse associationCox proportional hazardsSerous ovarian cancerRisk of breastBRCA1 mutation carriersPathogenic BRCA2 variantsControl patientsCase patientsInverse associationOdds ratioProstate cancerMutation carriersProportional hazardsObesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium
Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A, Fereday S, Hung J, Johnatty SE, Fasching P, Beckmann M, Lambrechts D, Vergote I, Van Nieuwenhuysen E, Lambrechts S, Risch H, Rossing M, Doherty J, Wicklund K, Chang-Claude J, Goodman M, Ness R, Moysich K, Heitz F, du Bois A, Harter P, Schwaab I, Matsuo K, Hosono S, Goode E, Vierkant R, Larson M, Fridley B, Høgdall C, Schildkraut J, Weber R, Cramer D, Terry K, Bandera E, Paddock L, Rodriguez-Rodriguez L, Wentzensen N, Yang H, Brinton L, Lissowska J, Høgdall E, Lundvall L, Whittemore A, McGuire V, Sieh W, Rothstein J, Sutphen R, Anton-Culver H, Ziogas A, Pearce C, Wu A, Webb P. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. British Journal Of Cancer 2015, 113: 817-826. PMID: 26151456, PMCID: PMC4559823, DOI: 10.1038/bjc.2015.245.Peer-Reviewed Original ResearchConceptsProgression-free survivalBody mass indexOvarian cancer-specific survivalCancer-specific survivalOvarian cancerHazard ratioHistologic subtypeOverall survivalHigh-grade serous cancerHigher Body Mass IndexInvasive ovarian cancerPooled hazard ratioDifferent histologic subtypesOvarian Cancer Association ConsortiumMajority of womenRandom-effects modelAdverse survivalPooled HRsSerous cancerEndometrioid subtypeMass indexOvarian carcinomaObservational studyModest associationCancer
2013
Preventing ovarian cancer through genetic testing: a population‐based study
Finch A, Bacopulos S, Rosen B, Fan I, Bradley L, Risch H, McLaughlin JR, Lerner‐Ellis J, Narod SA. Preventing ovarian cancer through genetic testing: a population‐based study. Clinical Genetics 2013, 86: 496-499. PMID: 24199689, DOI: 10.1111/cge.12313.Peer-Reviewed Original ResearchConceptsOvarian cancerGenetic testingGenetic testing criteriaInvasive ovarian cancerPopulation-based studyOvarian cancer patientsBRCA2 gene mutationsGenetic test resultsDevelopment of cancerCancer patientsBRCA2 mutationsMutation carriersUnselected casesEligibility criteriaCancerPatientsGene mutationsProvince of OntarioWomenPotential utilityPopulation levelBRCA1MutationsLong-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2
McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P, Narod SA. Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2. Journal Of The National Cancer Institute 2013, 105: 141-148. PMID: 23257159, PMCID: PMC3611851, DOI: 10.1093/jnci/djs494.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerOvarian cancerBRCA2 mutationsLong-term survival benefitOvarian cancer-specific survivalCancer-specific survivalOvarian cancer survivalSerous ovarian cancerShort-term survival advantageBRCA1 mutation carriersLong-term survivalHazard ratioSurvival benefitBetter prognosisUnselected womenBRCA2 carriersCancer survivalMutation carriersSurvival advantageSurvival analysisCancerDiagnosisTime pointsWomenSurvival
2012
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies
Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A, Consortium O. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. The Lancet Oncology 2012, 13: 385-394. PMID: 22361336, PMCID: PMC3664011, DOI: 10.1016/s1470-2045(11)70404-1.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerSelf-reported endometriosisHistory of endometriosisCase-control studyHistological subtypesOvarian cancerBorderline tumorsOvarian cancer case-control studiesOral contraceptive useBorderline ovarian cancerSubset of womenEpithelial ovarian cancerDanish Cancer SocietyCancer case-control studyOvarian Cancer Association ConsortiumUK National InstituteNational InstituteLogistic regression analysisCancer Research FundCancer Research ProgramMedical Research CouncilCancer Research CenterUS Army Medical ResearchInvasive casesPooled analysis
2011
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecologic Oncology 2011, 121: 353-357. PMID: 21324516, DOI: 10.1016/j.ygyno.2011.01.020.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerOvarian cancerFirst-degree relativesMultiplex ligation-dependent probe amplificationUnselected patientsBRCA2 mutationsNon-mucinous ovarian cancerGermline mutationsCombined mutation frequencyPopulation-based seriesOvarian cancer patientsCommon adult cancersSerous ovarian cancerPrevalence of mutationsFrequency of BRCA1Mucinous carcinomaCancer patientsAdult cancersLigation-dependent probe amplificationCancerGenetic testingPatientsWomenBreastBRCA1
2008
Uptake of clinical genetic testing for ovarian cancer in Ontario: A population-based study
Metcalfe KA, Fan I, McLaughlin J, Risch HA, Rosen B, Murphy J, Bradley L, Armel S, Sun P, Narod SA. Uptake of clinical genetic testing for ovarian cancer in Ontario: A population-based study. Gynecologic Oncology 2008, 112: 68-72. PMID: 19019415, PMCID: PMC3074978, DOI: 10.1016/j.ygyno.2008.10.007.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerClinical genetic testingOvarian cancerGenetic testingGenetic test resultsBlood samplesPositive genetic test resultOntario Cancer RegistryPopulation-based studyEpithelial ovarian cancerProportion of womenCancer RegistryRisk factorsBRCA2 mutationsClinical testingCancerWomenBRCA2BRCA1Small proportionPrevious testingMutationsPatientsTestingRegistryOvarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1
Harley I, Rosen B, Risch HA, Siminovitch K, Beiner ME, McLaughlin J, Sun P, Narod SA. Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1. Gynecologic Oncology 2008, 109: 384-387. PMID: 18405947, PMCID: PMC3060029, DOI: 10.1016/j.ygyno.2007.11.046.Peer-Reviewed Original ResearchConceptsHereditary non-polyposis colon cancer syndromeInvasive ovarian cancerOvarian cancerMLH1 genePolymorphic variantsOvarian cancer riskColon cancer syndromesMismatch repair genes MLH1Endometrial cancerClear cellsCancer riskCardinal featuresCancer syndromesCancerGenes MLH1Proportion of familiesSignificant riskSyndromeColonCommon variantsRiskEthnic groupsPredisposesHistologyVariants
2007
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA, Group O. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. The Lancet Oncology 2007, 8: 26-34. PMID: 17196508, DOI: 10.1016/s1470-2045(06)70983-4.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerCarriers of BRCA1Case-control studyOral contraceptivesOvarian cancerBRCA2 mutationsTubal ligationRisk factorsBRCA1 mutationsReproductive risk factorsPopulation-based studyOvarian cancer riskPossible adverse effectsYear of birthInternational registryMenstrual cycleOdds ratioBreast cancerMutation carriersReproductive historyContraceptivesBRCA2 genesCancerAdverse effectsWomen
2006
Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada. Journal Of The National Cancer Institute 2006, 98: 1694-1706. PMID: 17148771, DOI: 10.1093/jnci/djj465.Peer-Reviewed Original ResearchConceptsIncident ovarian cancerAge 80 yearsGeneral Ontario populationOvarian cancerBRCA2 mutationsTypes of cancerMutation carriageCumulative incidenceRelative riskBreast cancerHigh riskGeneral populationBRCA1 mutationsInvasive ovarian cancerCancer incidence ratesFirst-degree relativesBRCA2 mutation frequencyOntario populationUnselected patientsMale breastTestis cancerCancer outcomesPancreatic cancerIncidence rateCancer risk